Alteogen Healthcare announced on the 3rd that it held a board meeting on the 31st and appointed Jin-guk Go as its CEO.
CEO Jin-guk Go graduated from Yonsei University with a degree in Biotechnology and completed an MBA at Yonsei University Graduate School of Business. He was in charge of marketing and sales at LG Life Sciences and led the launch and growth of various new products at Janssen Korea, the pharmaceutical division of the global pharmaceutical company Johnson & Johnson (JNJ).
Recognizing his experience and capabilities, he joined Alteogen Healthcare, a subsidiary responsible for sales and marketing of Alteogen's proprietary products to be developed in the future, starting with Tergaseju, as Vice President, and was appointed CEO this year. Former CEO Jae-sang Lee will support the company's sustainable growth as an advisor.
CEO Jin-guk Go stated, "Based on the unrivaled technology and market competitiveness of 'Tergase,' the first recombinant hyaluronidase in Korea, we will achieve the number one position domestically and focus on expanding into the global market and broadening our business areas."
Currently, Alteogen Healthcare is responsible for sales and marketing of growth hormone and adhesion prevention agent Protescal, as well as the hyaluronidase product Tergase. In particular, after Tergaseju received sales approval from the Ministry of Food and Drug Safety at the end of last year, it has passed the Drug Committees (DC) of over 40 general hospitals, including Seoul Asan Medical Center and Kyungpook National University Hospital. The company aims to pass the DC of more than 100 general hospitals within this year. Additionally, a joint promotion with PharmaResearch, which handles clinics and hospitals, is underway, expecting strong synergy.
Going forward, leveraging its high-purity product, which differs from existing animal-derived products, the company plans to actively enter not only the domestic market but also overseas markets.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
